08.13.2009

PharmaGap Advised By U.S. National Cancer Institute Of Positive Results Of Testing for the Company’s Lead Cancer Drug GAP-107B8

Ottawa, Ontario/August 13, 2009 – PharmaGap Inc. (TSX-V: GAP; OTC.BB-PHRGF) (“PharmaGap” or “the Company”) has been advised by the U.S. National Cancer Institute (“NCI”) that the Company’s lead cancer drug GAP-107B8 (formerly known as PhG-alpha-1) has demonstrated sufficient anti-proliferative effect in the NCI’s initial single dose assay to warrant examination in an expanded “dose response” assay in which the compound will be evaluated against the NCI-60 cancer cell panel at five concentration levels. The NCI has further advised that the threshold for progression to the dose response assay is based on results in the single dose assay in comparison with historical data of compounds screened by the NCI that were of sufficient interest for review by the NCI’s DTP Biological Evaluation Committee. The NCI-60 protocol tests a wide variety of cancers, including breast, colorectal, lung, ovarian, kidney, prostate, leukemia and various central nervous system cancers and melanomas. A complete outline of the NCI’s compound screening process can be found at http://dtp.cancer.gov/screening.html.

The Company has not yet received the data from the single line screen for analysis, and accordingly cannot provide further comment until such data is received and analyzed. The Company will announce the full results and interpretation of data following receipt of data from the NCI.

The Company provides this update in advance of receipt of full test data in order to ensure full compliance with the Company’s continuous disclosure obligations, in light of recent market activity in the Company’s shares.

About The National Cancer Institute
The National Cancer Institute (“NCI”) is an institute of the National Institutes of Health, the primary U.S. Federal Agency for conducting and supporting medical research. The NCI’s mandate is to conduct and foster cancer research in the United States, and is located in Bethesda, Maryland.  For more information please visit www.cancer.gov.

About PharmaGap Inc.
PharmaGap Inc. (TSX-V: GAP), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel therapeutic compounds for the treatment of cancer. PharmaGap's research platform targets cellular signalling pathways controlled by Protein Kinase C (PKC) isoforms. PharmaGap's lead drug compound, PhG-alpha-1, is in preclinical development and targets PKC alpha. The Company's strategy is to out-license drug compounds to larger life sciences companies at the preclinical stage. For more information on PharmaGap please visit the Company's website at www.pharmagap.com.

For information relating to this Release, please contact:
Robert McInnis, President & CEO
(613) 990-9551 bmcinnis@pharmagap.com

Note: The TSX-Venture Exchange does not accept responsibility for the adequacy or accuracy of this release. No Securities Commission or other regulatory authority having jurisdiction over PharmaGap has approved or disapproved of the information contained herein. This release contains forward looking statements that may not occur or may change materially.